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organic/inorganic labels have been devel-
oped for the detection and imaging of ana-
lytes, biological systems, diseased tissues, 
or events.[4–6] For imaging tissues by laser-
scanning confocal fluorescence micros-
copy, typical exogenous luminescent 
probes offer imaging depths of only a few 
tens of micrometers, owing to the scat-
tering of light and interference of tissue 
autofluorescence from intrinsic fluoro-
phores such as riboflavin, flavoproteins, 
and nicotinamide adenine dinucleotide.[7,8] 
Two-photon microscopy (TPM) provides 
a means to increase penetration depth 
and improve spatial resolution due to 
the reductions in tissue autofluorescence 
and scattering associated with the longer 
wavelengths of both the exciting and emitting photons.[9,10] 
Thus, TPM has been employed as a minimally invasive tool for 
numerous short-term and long-term animal studies.[11]
Semiconductor nanocrystals have been harnessed as one 
or two-photon imaging agents to monitor cellular trafficking, 
A major obstacle in luminescence imaging is the limited penetration of vis-
ible light into tissues and interference associated with light scattering and 
autofluorescence. Near-infrared (NIR) emitters that can also be excited with 
NIR radiation via two-photon processes can mitigate these factors somewhat 
because they operate at wavelengths of 650–1000 nm where tissues are more 
transparent, light scattering is less efficient, and endogenous fluorophores 
are less likely to absorb. This study presents photolytically stable, NIR photo-
luminescent, porous silicon nanoparticles with a relatively high two-photon-
absorption cross-section and a large emission quantum yield. Their ability 
to be targeted to tumor tissues in vivo using the iRGD targeting peptide is 
demonstrated, and the distribution of the nanoparticles with high spatial 
resolution is visualized.
Cancer Diagnostics
Photoluminescence (PL) is a versatile tool in chemical, bio-
logical, and biomedical science as it enables operationally 
simple, cost-effective, noninvasive, sensitive, and rapid visu-
alization of organisms at a subcellular level with high reso-
lution.[1–3] Accordingly, various kinds of photoluminescent 
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tumor microenvironments, and tissue vasculature.[12–16] These 
materials typically show remarkable photostability compared 
with organic dyes, and some display sufficient two-photon 
absorption cross-sections (TPACS, δ) to be of use in two-
photon imaging schemes.[17,18] Silicon-based nanocrystals have 
emerged as promising substitutes for toxic cadmium or lead-
based semiconductor nanocrystals;[19–21] the aqueous degra-
dation product of mesoporous silicon is principally Si(OH)4, 
which is the form of silicon naturally present in tissues of the 
body.[22] As nanoparticles, the mesoporous form of silicon has 
been shown to be useful for drug delivery applications, where 
the 50–80% void volume leads to relatively high capacity for 
protein, small molecule, or nucleic acid payloads (typical mass 
loadings in the range of 10–20%).[23–25] The utility of porous 
silicon nanoparticles (pSiNPs) has been enhanced by the incor-
poration of tissue-specific targeting elements, which can reduce 
the overall dose needed to effect productive therapeutic or 
imaging results in vivo.
One-photon photoluminescence from quantum-confined 
pSiNPs has been effectively harnessed for bioimaging due to 
their tissue-penetrating near-infrared (NIR) emission,[26–29] 
although applications are limited by the short wavelengths 
needed for efficient excitation (300–450 nm). Imaging silicon 
nanoparticles (both porous and solid forms) via two-photon 
excitation has been reported.[30–33] While this has the potential 
to provide tissue images at greater depths and at higher resolu-
tion, no live animal imaging results with intravenously admin-
istered silicon nanoparticles have yet been reported, presum-
ably due to their relatively low TPACS and low accumulation in 
the imaged tissues. Here we demonstrate the utility of pSiNPs 
for in vivo two-photon imaging by optimizing the pSiNP size to 
maximize TPACS and by adding a peptide targeting group to 
selectively accumulate the nanoparticles in tumor tissues.
The pSiNPs were prepared from highly doped p-type single-
crystal silicon wafers in aqueous ethanolic electrolytes con-
taining HF (hydrofluoric acid), using an electrochemical per-
foration etch followed by liftoff, ultrasonic fracture, aging, and 
isolation as previously described.[34] The perforation etch yields 
pSi particles with well-controlled particle size and distribution. 
In the present case, we prepared two size classes for compar-
ison, one of nominal hydrodynamic diameter 60 nm and the 
other of nominal diameter 230 nm, denoted as 60 nm pSiNPs 
and 230 nm pSiNPs, respectively (measured by dynamic light 
scattering (DLS); Figure 1a–c, see Figures S1–S3 in the Sup-
porting Information). The ultrasonic fracture process gener-
ated a native oxide on the porous Si skeleton (Figure 1a), and 
this SiO2 sheath imparted a negative zeta potential (−37.4 ± 
3.8 mV; Table S1, Supporting Information) to the nanopar-
ticles. The samples displayed bands in the infrared spectrum 
consistent with a hydroxylated silicon oxide (Si–O stretching 
mode at 1020 cm−1 and O–H stretching and bending modes at 
3300 cm−1 and 1640 cm−1, respectively; Figure S3, Supporting 
Information). The X-ray photoelectron spectra (XPS) were con-
sistent with the existence of a surface oxide layer on the nan-
oparticles (Figure 1d). Raman spectroscopy (Si lattice mode 
at 515 cm−1; Figure S3, Supporting Information) and powder 
X-ray diffraction (XRD) (Figure S3, Supporting Information) 
analysis showed the pSiNPs retained a crystalline silicon skel-
eton, although there was a broadening of the peaks associated 
with crystalline silicon post-ultrasonication. The ultrasonication 
process also induced a decrease in the total pore volume and 
average pore diameter as measured by nitrogen absorption–
desorption isotherm analysis, consistent with the growth of 
a SiO2 sheath on the surface of the pore walls (Figure S4 and 
Table S2, Supporting Information).
The growth of the SiO2 sheath activated PL from the nano-
particles (Figure 1e); the increase in the PL signal is attributed 
to passivation of nonradiative surface defects by the oxide layer. 
The PL (λex = 365 nm) from the 60 nm pSiNPs became detect-
able after 12 h of ultrasonic fracture, and the intensity of PL 
maximized at an emission wavelength of 780 nm after ≈48 h of 
ultrasonication (Figure 1e and Figure S5, Supporting Informa-
tion). The PL intensity was observed to decrease after 48 h of 
ultrasonication (Figure S5, Supporting Information), presum-
ably due to degradation and dissolution of the nanoparticles. 
The radiative recombination of electron–hole pairs confined in 
crystalline silicon domains is reported to occur at dimensions 
smaller than 5 nm, approximately the exciton diameter for crys-
talline silicon.[35] The calculated crystallite size in the skeleton 
of the 60 nm pSiNPs, determined using the Debye–Scherrer 
formula from powder XRD data, was 1.5 nm (see Figure S3 
and the formula in the Supporting Information). Thus, the 
nanoparticles can be considered to consist of an ensemble of 
quantum-confined domains dispersed in the nanoparticle skel-
eton. Using rhodamine 6G as a standard, the 60 nm pSiNPs 
showed a quantum yield of 22.3% (Figure S6, Supporting Infor-
mation), substantially greater than the 9.4% quantum yield of 
the larger 230 nm pSiNP preparation (Figure S7, Supporting 
Information).[30] The reason for the greater quantum yield 
of the smaller pSiNPs is not clear at this time, but it may be 
due to the presence of fewer quantum-confined domains in 
a given nanoparticle that can undergo proximal quenching. 
Alternatively, the smaller nanoparticles may possess a more 
complete passivating oxide shell.[36] As expected for quantum-
confined silicon,[35] the PL emission lifetime for both nano-
particle formulations was on the timescale of microseconds 
(PL half-life measured at λem = 780 nm of 106 and 121 µs for 
230 nm pSiNPs and 60 nm pSiNPs, respectively; Figure S8 and 
Table S3, Supporting Information).
We next determined the two-photon transition probability 
of the pSiNPs using luminescence correlation spectroscopy. 
We scanned the excitation wavelength range from 750 to 
1050 nm and collected emission signals in the wavelength range 
560–740 nm to avoid interference of the excitating photons with 
the pSiNP emission spectrum (Figure 1e). For a process in which 
excitation results from simultaneous absorption of two photons, 
the luminescence emission intensity is expected to depend quad-
ratically on average excitation power Pex, or IPL = (Pex)2 × Δt × C, 
where IPL is the amount of photo luminescence light detected, 
Δt is the duration of the pulsed excitation, and C represents 
constants associated with the experimental setup.[37] The meas-
urements were carried out by varying the incident power and 
recording the corresponding emission intensities for two sepa-
rate excitation wavelengths, 800 and 850 nm. A log–log plot of 
emission intensity versus incident power yielded a slope of ≈2.0, 
as expected for a two-photon absorption process (Figure 2a). 
Under two-photon excitation conditions (λex = 850 nm), strong 
PL was only observed at the focal point of the exciting beam, 
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in contrast to the PL observed along the entire beam path for 
one-photon excitation (λex = 365 nm) (Figure 2b).
The TPACS (δ) of the 60 nm pSiNPs were determined in 
the excitation range 750–1050 nm using rhodamine 6G as a 
reference (Figure 2c).[38,39] The maximum TPACS from 60 nm 
pSiNPs was found to be 5.57 GM (Göeppert-Mayer, 1 GM = 
10−50 cm4 s−1 per photon), and it occurred at an excitation wave-
length of λex = 800 nm (Figure 2d; for calculation see the Exper-
imental Section). The TPACS of the 60 nm pSiNPs was sub-
stantially larger than the corresponding TPACS of the 230 nm 
pSiNPs at λex = 800 nm (5.57 GM vs 1.86 GM for 60 nm and 
230 nm pSiNPs, respectively; Figure 2e). For comparison, the 
maximum TPACS for rhodamine 6G in this wavelength range 
is 55 GM (at λex = 750 nm).[39] However, the 60 nm pSiNPs 
showed superior photostability compared with the organic 
dye when subjected to two-photon excitation; negligible emis-
sion changes were observed with 20 mW of laser excitation 
(λex = 850 nm) over a period of 60 min, whereas rhodamine 
6G showed a 40% loss in intensity under the same condi-
tions (Figure 2f). The resilience demonstrated by the pSiNPs 
is important for biological imaging applications where longer 
measurement timescales might be needed and where chromo-
phore photostability can be a limiting factor, such as assaying 
protein activity, monitoring cellular redox potentials, tracking 
cell migration, and quantifying accumulation or clearance of 
probes in tissues.
We next evaluated the nanoparticles as two-photon imaging 
agents in a tissue-specific targeting application. For this study 
we chose the tumor-homing peptide iRGD (sequence: CRGD-
KGPDC), for two main reasons: 1) it is known to provide selec-
tive targeting to (neuropilin-positive) tumor cells;[40] and 2) it 
has also been shown to be highly effective in targeting pSiNPs 
to tumors in a mouse xenograft model.[41] Due to their supe-
rior two-photon cross-section, these studies used the 60 nm, 
rather than the 230 nm pSiNP formulation. The peptide was 
attached to the pSiNPs via a bifunctional poly(ethylene-glycol) 
Adv. Mater. 2017, 29, 1703309
Figure 1. Preparation and characterization of 60 nm pSiNPs. a) Schematic illustration of the skeleton-sheath Si-SiO2 structure of the porous silicon 
nanoparticles used in this study. b) Transmission electron microscope (TEM) images of the pSiNPs. These particles were prepared by ultrasonica-
tion in deionized water for 48 h. c) Mean hydrodynamic diameter (intensity distribution) of nanoparticles that were ultrasonicated for the indicated 
time periods, measured by dynamic light scattering (DLS). Particles were isolated at the indicated time points, rinsed, and redispersed in deionized 
water (DI H2O) for the measurement. d) X-ray photoelectron spectra (XPS) in the Si2p and O1s regions of nanoparticles that were ultrasonicated for 
the indicated time periods. “As-etched” refers to the as-etched pSi film, prior to ultrasonication. Assignments: SiO/SiO2 at 102–104 eV (Si2p) and 
532.5 eV (O1s). e) Absorbance and photoluminescence emission spectra of the 60 nm pSiNP formulation. Photoluminescence measured in ethanol 
using ultraviolet excitation (λex = 365 nm). The inset photograph obtained under UV illumination (365 nm).
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(PEG) linker (Figure 3a) as follows (Figure S9, Supporting 
Information): a cysteine thiol on the peptide was coupled to a 
maleimide group on one end of the PEG linker; the other end of 
the linker contained a succinimidyl valerate group, which was 
coupled to a free amine on the pSiNP surface. The free amine 
groups on the pSiNP surface were previously generated by 
hydrolytic condensation of 2-aminopropyldimethylethoxysilane 
(APDMES). The mean hydrodynamic diameter of the resulting 
construct (named, “60 nm pSiNP-iRGD”) increased from the 
original 60 to 90 nm (mean z-average, intensity based), indi-
cating that the conjugation chemistry placed an ≈15 nm corona 
around the pSiNP core. The polydispersity index measured by 
DLS was <0.2, indicating that there was no substantial aggre-
gate formation caused by the conjugation chemistry (Figure S9, 
Supporting Information). The PL intensity of the pSiNP-iRGD 
construct under two-photon excitation (λex = 850 nm, power = 
20 mW) was similar to the pSiNP starting material, and it simi-
larly showed good stability during 60 min of exposure to the 
excitation source (Figure S9, Supporting Information). The 
longer-term stability of the nanoparticle construct was assessed 
in a simple pH 7.4 buffer solution maintained at 37 °C, using 
one-photon photoluminescence measurements. Under UV 
excitation (λex = 365 nm), the 60 nm pSiNP-iRGD construct lost 
≈20% of its PL intensity within 1 h, 50% within 2 h, and PL was 
near zero after 24 h (Figure S10, Supporting Information).
When incubated with HeLa cells, in vitro cellular TPM 
images indicated significant uptake of the 60 nm pSiNP-iRGD 
(Figure 3b and Figure S11, Supporting Information). The nan-
oparticles localized to the cytosol of the cells and displayed a 
greater level of cellular uptake relative to untargeted control 
pSiNPs, consisting of bare pSiNPs (containing just a simple 
oxide coating) or where the PEG-linker was present but the 
peptide was replaced with a methoxy group (“pSiNP-mPEG”).
We next performed a series of experiments to determine if 
normal tissues would interfere with the two-photon imaging 
modality used to detect the pSiNPs. For this evaluation we dis-
sected individual organs (brain, kidney, lung, spleen, and liver) 
from mice and then incubated them (2 h, 37 °C) in phosphate-
buffered saline (PBS) control or in a solution of untargeted, 
oxide-coated 60 nm pSiNPs (10 mg mL−1). Both one-photon 
(confocal laser scanning microscope, CLSM) and two-photon 
images were obtained (Figure S12, Supporting Information). 
Whereas control tissue samples incubated in buffer only dis-
played minimal PL signals in the observation channel in either 
one-photon or two-photon imaging modalities, all organs incu-
bated with pSiNPs displayed strong PL signals (Figure S13, 
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Figure 2. Two-photon photoluminescence characteristics of 60 nm pSiNPs. a) Log–log plot showing laser power dependence of the photoluminescence 
intensity from 60 nm pSiNPs dispersed in DI H2O. The pSiNPs were excited using a Ti:sapphire laser emitting at 800 nm (black squares) or 850 nm (red 
circles), and photoluminescence intensity was collected in the wavelength range 560–740 nm (see the Materials and Methods section in the Supporting 
Information). b) Photographs showing illumination of a dispersion of 60 nm pSiNPs in DI H2O using one-photon excitation (λex = 365 nm, light comes 
from right) and focused two-photon excitation (λex = 850 nm, power = 100 mW). Scale bar is 1.0 mm. c) Two-photon photoluminescence intensity as 
a function of λex for 60 nm pSiNPs, rhodamine 6G, and DI H2O control. The pSiNP and rhodamine 6G samples were dissolved in DI H2O. Samples 
were excited at the indicated two-photon excitation wavelength and the photoluminescence intensity was quantified in the range 560–740 nm. The same 
laser power (4.8 mW) was applied for each measurement. d) Two-photon absorption cross-sections (GM) of 60 nm pSiNPs in DI H2O as a function 
of excitation wavelength. The error bars represent standard deviation calculated from triplicate measurements (see details in the Supporting Informa-
tion). e) The two-photon-induced photoluminescence intensity of 60 nm pSiNPs and 230 nm pSiNPs in DI H2O, measured at excitation wavelengths 
of 800 and 850 nm, as indicated. The same laser power (4.8 mW) was applied, and the photoluminescence intensity was quantified by integration over 
the wavelength range 560–740 nm. Standard deviations calculated from triplicate measurements. Each sample contained the same concentration of 
pSiNPs (1 mg mL−1) or rhodamine 6G (1 µm). f) Comparison of photostability of 60 nm pSiNPs and Rho-6G in DI H2O under two-photon excitation 
conditions (λex = 850 nm, laser power = 20 mW). Relative photoluminescence intensity was monitored for 60 min at 2 min intervals. The PL signal was 
collected over the wavelength range 560–740 nm.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1703309 (5 of 8)
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Supporting Information). The signals were more pronounced 
in the near-surface region of the organs, though the two-photon 
images showed stronger signals from the pSiNPs at depths 
>30 µm into the tissues relative to one-photon CLSM, as can 
be expected from the greater penetration depth of the two-
photon imaging modality (Figures S12 and S13, Supporting 
Information).
Finally, we evaluated the ability of the targeted pSiNPs to image 
a near-surface tumor by TPM, using a mouse xenograft tumor 
model and the 60 nm pSiNPs-iRGD formulation as the imaging 
agent. Tumor-bearing mice were prepared by subcutaneous 
inoculation of HeLa cells in the dermal layer (>200 µm depth) of 
the right hind limb (Figure 3c; see the Materials and Methods sec-
tion in the Supporting Information). Prior to imaging, the mor-
phological properties of the tumor (Figure 3b, right) and normal 
(Figure 3b, left) tissue regions were evaluated using optical coher-
ence tomography (OCT).[42,43] The angiographic OCT images 
revealed randomly distributed, undefined blood vessels in the 
region surrounding the tumor nodule, and the cross-sectional y–z 
axis-scanned OCT images provided in-depth information on the 
tissues: epidermal layer (0–50 µm from skin surface) and dermal 
layer (below 50 µm) (Figure S14, Supporting Information).
Adv. Mater. 2017, 29, 1703309
Figure 3. In vitro and in vivo two-photon microscope images of porous Si nanoparticles selectively targeted to tumor tissues. a) Schematic illustra-
tion depicting the structure of the 60 nm pSiNP-iRGD construct used (iRGD-specific targeting peptides attached to the pSiNP via 5 kDa PEG linkers, 
“pSiNP-iRGD”). b) In vitro TPM images of HeLa cells treated with targeted and control 60 nm pSiNPs (20 µg per well) after 30 min incubation at 
37 °C. The designation “pSiNP” represents control 60 nm pSiNPs containing only a native oxide surface chemistry. The designation “pSiNP-mPEG” 
represents control pSiNPs containing the 5 kDa PEG linkers, but each PEG is terminated with a methoxy group instead of the targeting peptide. Laser 
power 10 mW at the focal plane. c) Photograph of xenograft tumor in the hind limb of a mouse, obtained under ambient light, showing the regions 
where the in vivo TPM images were collected for normal (blue, left) and tumor (red, right) tissue samples. d) Intensity of signals extracted from TPM 
images of live animals, obtained in the tumor region for mice injected with 60 nm pSiNP-iRGD (20 mg kg−1, n = 4) or with PBS control (n = 4), moni-
tored as a function of time postinjection. Time point 0 represents measurements made on animals prior to injection. Laser power ≈50 mW at the focal 
plane. The intensity data were derived from the TPM images at a depth of 140 µm from the epidermal surface of the animal (along the z-direction), 
and the inset images correspond to the same depth, obtained 60 min postinjection. Scale bar is 35 µm. e) In vivo TPM images of tumor region 
acquired at the indicated depths, 60 min postinjection of 60 nm pSiNP-iRGD (20 mg kg−1). Laser power ≈50 mW at the focal plane. The images shown 
are representative images out of 30 sectional images obtained from depths in the range 100–250 µm. The red and blue signals were collected in the 
wavelength range 560–740 and 400–430 nm, respectively, corresponding to the pSiNP and the collagen signals, respectively. f) Sections from in vivo 
TPM images from normal and tumor regions, obtained at a depth of 140–215 µm prior to injection (control) and 60 min postinjection of either PBS 
or 60 nm pSiNP-iRGD. g) Ex vivo TPM images of organs harvested from animals that were sacrificed 60 min postinjection of 60 nm pSiNP-iRGD (tail-
vein injection, 20 mg kg−1). The images shown are representative images obtained at a depth of 45–165 µm. h) Biodistribution of pSiNP-iRGD derived 
from measured PL intensity from the ex vivo TPM images of panel (g). The percentages represent relative PL intensity from each organ after baseline 
subtraction; baseline values for each organ were obtained from the PBS-injected controls. All TPM images were obtained with 850 nm excitation, and 
emission intensity was measured in the wavelength range 560–740 nm.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1703309 (6 of 8)
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TPM images were then monitored in the region of the tumor 
nodule. The 60 nm pSiNP-iRGD construct (20 mg kg−1) was 
administered via intravenous tail-vein injection and moni-
toring commenced 25 min postinjection, to ensure sufficient 
time for blood circulation. The data showed substantial two-
photon signals in the dermal layers (125–155 µm) compared 
with the PBS-injected control, indicative of accumulation of the 
nanoparticles in the tumor region (Figure 3d and Figure S15, 
Supporting Information). The two-photon emission signal 
was relatively stable throughout the 1 h monitoring period. 
The depth dependence of the TPM signal was assessed from 
the superficial dermal layer (100–150 µm from the skin) to the 
internal dermal layer (200–250 µm from the surface) at regular 
intervals (15 µm) in the tumor region, for a period of 60 min 
post-injection (Figure 3e, and Figure S16 and Movies S1–S2, 
Supporting Information). The PL emission signal was recorded 
in two wavelength channels: 400–430 nm, the region where the 
second harmonic generation (SHG) signal from collagen fibers 
in the dermal layer appears;[44] and 560–740 nm, the emission 
window for the 60 nm pSiNP-iRGD construct. Images were 
acquired under the same two-photon excitation conditions 
(λex = 850 nm, power = 50 mW). The SHG signal from collagen 
was strong in the superficial dermal layer (blue channel in 
Figure 3e), and the signal from the nanoparticles was strongest 
in the zone between 170 and 215 µm from the skin surface 
(internal dermal layer, red channel in Figure 3e). The z-stacked 
TPM images of normal and tumor regions at 140–215 µm 
depths, obtained before injection and after injection of the 
60 nm pSiNP-iRGD construct, showed selective accumula-
tion of the nanoparticles. Control injections of PBS showed no 
significant interference from biological tissues (Figure 3f and 
Figures S16 and S17, Supporting Information).
The in vivo TPM imaging capability of pSiNPs was com-
pared to the standard two-photon absorber rhodamine 6G. Both 
probes were injected locally into the dermis near the tumor 
(at a depth of ≈200 µm from the surface). We chose a local-
ized injection because systemically administered rhodamine 
6G shows no organ or tumor specificity. For TPM images of 
approximately comparable intensity (Figure S18, Supporting 
Information), the pSiNP dose needed to be much larger (40 µg) 
relative to rhodamine 6G (20 ng). This reflects the substantially 
lower two-photon absorption cross-section (Figure 2) and the 
lower emission quantum yield (Figure S6, Supporting Informa-
tion) of the pSiNPs relative to rhodamine 6G. Thus although 
the present in vivo TPM results demonstrate that the combina-
tion of NIR emission and NIR two-photon excitation can sub-
stantially improve the image quality relative to one-photon, UV 
excitation, the pSiNPs are substantially weaker than a standard 
molecular TPM probe. The low toxicity of the silicon system, its 
ability to carry therapeutic payloads, and its ability to selectively 
and multivalently target tissues offer substantial advantages to 
motivate further studies to improve the two-photon cross-sec-
tion of the silicon nanomaterial.
Distribution and histological studies of the organs collected 
from the same mice (n = 4) 60 min postinjection were analyzed 
by ex vivo TPM imaging and hematoxylin/eosin staining. In the 
TPM images, substantially higher PL intensity was observed 
in the tumor (hind limb) in comparison with the main organs 
(brain, kidney, liver, and lung) and PBS-injected control mice 
(n = 4) (Figure 3g,h and Figure S19, Supporting Informa-
tion). The biodistribution data are consistent with the selective 
homing property previously seen for peptide-targeted pSiNP 
formulations.[41,45,46] Histopathology showed no significant 
toxicity in the tissues relative to the control (Figure S20, Sup-
porting Information).
This study represents the first example of two-photon 
imaging of pSiNPs in live animals, and it demonstrates a 
potential application in selective tumor imaging. The tumor 
imaging demonstration presented in this work highlights two 
advantages of pSiNPs as imaging agents: their multivalent tar-
geting capability for selective tissue homing and their low sys-
temic toxicity. The 60 nm pSiNP formulation showed higher 
quantum yield (22.3%) and greater two-photon absorption 
cross-section (5.57 GM at 800 nm, 4.29 GM at 850 nm) rela-
tive to larger pSiNPs. While the two-photon absorption cross-
section is modest relative to standard molecular two-photon 
imaging agents such as rhodamine 6G, the photostability under 
excitation conditions was found to be substantially greater.
Experimental Section
Preparation of pSiNPs (60 nm Size): pSiNPs were prepared by 
electrochemical etching of highly doped p-type single-crystal silicon 
wafers in an electrolyte consisting of 3:1 (v:v) 48% HF:absolute ethanol. 
CAUTION: HF is highly toxic and corrosive and contact with skin 
should be avoided. Procedures involving HF should always be carried 
out in a fume hood configured to handle HF and the operator should 
wear appropriate protective gloves, gown, and face shield. The synthetic 
procedure is outlined in Figure S1 (Supporting Information). The 
Si wafers were contacted on the backside with a strip of Al foil. Prior 
to preparation of the porous layers, the wafer surfaces were cleaned 
using a sacrificial etch consisting of electrochemical anodization 
(60 s, 50 mA cm−2) in an electrolyte consisting of 3:1 (v:v) 48% aqueous 
HF:absolute ethanol, followed by ethanol rinse, then dissolution of the 
porous film with aqueous KOH (2 m). The wafer was rinsed with water 
and then with ethanol. A perforation etching waveform[34] was used to 
prepare the porous layers, which consisted of a current density pulse 
of 50 mA cm−2 of 0.60 s duration, followed by a current density pulse 
of 400 mA cm−2 of 0.363 s duration. This waveform was repeated for 
500 cycles, generating a porous nanostructure consisting of ≈60-nm-thick 
porous silicon layers separated by high porosity (“perforation”) layers 
(Figure S1, Supporting Information). The pSi layer was removed from 
the silicon substrate by application of a current pulse of 4 mA cm−2 
for 250 s in a solution containing 1:20 (v:v) aqueous HF:absolute 
ethanol (lift-off step). The freestanding films (≈63 mg) were fractured 
by ultrasound in deionized water (DI H2O, 6 mL) for 48 h and aged 
for 24 h at room temperature (25 °C). The resulting surface-oxidized 
porous Si-SiO2 frame-sheath nanoparticles were filtered twice through 
a syringe filter (first through Millipore, Millex syringe filter unit, 220 nm 
model #SLGP033RS, then a 100 nm model #SLVV033RS) and used 
without further purification. The concentration of the resulting pSiNP 
solution was ≈10 mg mL−1 in DI H2O (5 mL), yield: 80%. The duration 
of ultrasonication used in the above description was determined by a 
systematic optimization study, where nanoparticle size was analyzed as 
a function of time (12–60 h) of ultrasonication. The average size and size 
distributions were monitored by DLS and confirmed by transmission 
electron microscopy (TEM). The nanoparticle size became smaller over 
time, and the 48 h ultrasonication time was found to yield particles with 
average hydrodynamic diameters of ≈60 nm.
Grafting of PEG-iRGD to pSiNPs: The 60 nm pSiNPs were separated 
from the stock solution of pSiNPs prepared above by centrifugation 
(15 000 rpm, 15 min) using a centrifugal filter (Millipore, MRCF0R100). 
The as-collected pSiNP pellet (1 mg) was resuspended in ethanol (1 mL), 
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aminopropyldimethylethoxysilane (APDMES, 20 µL) was added, and the 
mixture was agitated for 4 h. The aminated nanoparticles (pSiNP-NH2) 
were then purified three times by centrifugation from ethanol to eliminate 
unbound APDMES. Then a solution (200 µL) of one of the desired 
heterofunctional linkers maleimide-PEG-succinimidyl valerate (MAL-
PEG-SVA, MW: 5000, 5 mg mL−1 in ethanol) or methoxy-PEG-succinimidyl 
valerate (mPEG-SVA, MW: 5000, 5 mg mL−1 in ethanol) was added to the 
aminated nanoparticles (1 mg in 800 µL) and agitated for 2 h. The resulting 
PEGylated nanoparticles (pSiNP-PEG or pPSiNP-mPEG) were isolated and 
purified by centrifugation/resuspension in fresh ethanol three times. For 
the peptide-conjugated (targeted) formulations, iRGD peptide (sequence 
CRGDKGPDC, cyclized between the two cysteine residues, 100 µL, 
1 mg mL−1 in DI H2O) was added to 100 µL of pSiNP-PEG in ethanol, 
incubated at 4 °C for 4 h, purified three times by centrifugation, dispersed 
in PBS (pH 7.4, 100 µL), and stored at 4 °C before use.
Photoluminescence Study of pSiNPs: Nanoparticles (either the 60 nm 
or the 230 nm sizes) were dispersed in ethanol, and photoluminescence 
intensity was measured using a cooled CCD (charge coupled device) 
spectrometer (OceanOptics QEPro) using a 365 nm LED (light-emitting 
diode) light source, a 370 ± 20 nm bandpass filter for excitation, and 
a 510 nm longpass emission filter. The integrated photoluminescence 
intensity was obtained in the wavelength range 500–980 nm. Plotted 
values represent average values (n = 4) with error bars representing 
1 standard deviation. For the experiments where PL intensity of pSiNPs 
was monitored as a function of time during aqueous dissolution, 
particles were dispersed in PBS (pH 7.4, 0.5 mg mL−1) and incubated at 
37 °C. The PL intensity was measured at each time point, and particles 
were transferred to fresh PBS using centrifugation (15 000 rpm, 15 min) 
through a centrifugal filter (Millipore, MRCF0R100).
Measurement of Two-Photon Cross-Sections of pSiNPs: The two-photon 
cross-section (δ) was determined using the femtosecond fluorescence 
measurement technique. Nanoparticles were dispersed in DI H2O and 
the two-photon-induced luminescence intensity was measured against a 
rhodamine 6G standard (QY = 0.95). 100 µL (1 mg mL−1) of each sample 
was loaded in single-well glass slides (CITOGLAS, Cat# 2306-0001, Citotest, 
China) and covered with a glass cover slip. The edges of the cover slip were 
coated with a transparent nail polish to prevent evaporation of solvent 
before mounting the slide on the vibration isolation table. The intensities 
of the two-photon-induced luminescence spectra of the reference and 
of pSiNPs were measured under the same excitation conditions. The 
two-photon cross-sections were calculated using the relationship δs = 
δr(SsΦrnrcr)/(SrΦsnscs), where the subscripts s and r stand for the sample 
and reference molecules, respectively; S is the integrated fluorescence 
intensity at focal plane; Φ is the fluorescence quantum yield; n is the overall 
fluorescence collection efficiency of the experimental apparatus; c is the 
number density of the molecules in solution, based on a mass estimation; 
and δr is the two-photon cross-section of the reference sample. The TPACS 
(GM) was calculated using the relationship GM = δmaxΦ; where Φ is the 
fluorescence quantum yield of the nanoparticles.[38,39,47]
Preparation of Mouse Xenograft Tumor Model and In Vivo TPM Imaging: 
All animal experimental procedures were conducted in accordance 
with institutional guidelines and regulations and approved by the 
Institutional Animal Care & Use Committee at POSTECH (approval 
number POSTECH-2015-0030-C1). Hairless mice (SKH1-HrHr, 6 weeks, 
female) were anesthetized via inhalation of a gas mixture of 1.5% v/v 
isoflurane (Terrell, Piramal, USA) and medical grade oxygen, and then 
HeLa cells (5 × 106 cells) were subcutaneously (SC) injected at the 
right side of the hind limb (dermis layer). TPM imaging was performed 
10 d after SC injection of the HeLa cells; tumor growth sufficient for 
the experiment was confirmed by naked eye and by OCT. The prepared 
mouse was placed on a custom-made hind limb holder, which was 
configured to maintain constant temperature and to provide positioning 
via a motorized X–Y translational stage. The 60 nm size pSiNP-iRGD 
formulation (20 mg kg−1) was intravenously injected via tail vein. In vivo 
TPM images were obtained with 850 nm excitation (50 mW laser power), 
and PL intensity was quantified in the wavelength range 560–740 nm. 
3D volumetric scanning was performed at 0.4 frames per second 
and a stepwise increment of 3 µm in the z-direction. For the control 
experiment, TPM imaging was performed under the same experimental 
conditions after intravenous tail-vein injection of PBS (200 µL) instead 
of pSiNPs. Time-lapse images were acquired for 60 min with a time 
interval of 6 min under constant experimental conditions.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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